The purpose of this study is to identify the effect of prophylactic entecavir in HBsAg Positive lymphoma patients treated with rituximab-based immunochemotherapy.
HBsAg Positive lymphoma patients are treated with entecavir when they receive rituximab-based immunochemotherapy. Entecavir 0.5mg daily is administrated from day 1 of immunochemotherapy and/or chemotherapy to 12 months after completing immunochemotherapy and/or chemotherapy.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
80
Entecavir 0.5mg daily from day 1 of immunochemotherapy and/or chemotherapy to 12 months after completing immunochemotherapy and/or chemotherapy. In patients with low load of hepatitis B virus DNA(≤2000 IU/ml), rituximab will be administrated at the beginning of entecavir prophylaxis. And in patients with high load of hepatitis B virus DNA(\>2000 IU/ml), rituximab will be administrated when hepatitis B virus DNA decreased to the level of 2000 IU/ml after entecavir prophylaxis.
Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, China
RECRUITING307 Hospital of the Chinese People's Liberation Army
Beijing, Beijing Municipality, China
the incidence of hepatitis B virus reactivation and hepatitis B virus reactivation related hepatitis
Time frame: from the beginning of immunochemotherapy and/or chemotherapy to 24 months after the last cycle of immunochemotherapy and/or chemotherapy
the incidence of hepatitis B virus virological response
Time frame: from the beginning of immunochemotherapy and/or chemotherapy to 24 months after the last cycle of immunochemotherapy and/or chemotherapy
the incidence of hepatitis B virus serological response
Time frame: from the beginning of immunochemotherapy and/or chemotherapy to 24 months after the last cycle of immunochemotherapy and/or chemotherapy
the incidence of hepatitis B virus maintained response
Time frame: from the beginning of immunochemotherapy and/or chemotherapy to 24 months after the last cycle of immunochemotherapy and/or chemotherapy
the incidence of hepatitis B virus sustained response
Time frame: from the beginning of immunochemotherapy and/or chemotherapy to 24 months after the last cycle of immunochemotherapy and/or chemotherapy
the incidence of hepatitis B virus relapse and relapse related hepatitis
Time frame: from the beginning of immunochemotherapy and/or chemotherapy to 24 months after the last cycle of immunochemotherapy and/or chemotherapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
309 Hospital of the Chinese People's Liberation Army
Beijing, Beijing Municipality, China
RECRUITINGAerospace Central Hospital
Beijing, Beijing Municipality, China
RECRUITINGAir Force General Hospital of the Chinese People's Liberation Army
Beijing, Beijing Municipality, China
RECRUITINGBeijing Hospital
Beijing, Beijing Municipality, China
RECRUITINGCancer Institute & Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
RECRUITINGFirst Hospital affiliated to General Hospital of the Chinese People's Liberation Army
Beijing, Beijing Municipality, China
RECRUITINGGeneral Hospital of Chinese People's Liberation Army
Beijing, Beijing Municipality, China
RECRUITINGPeking Union Medical College Hospital
Beijing, Beijing Municipality, China
RECRUITING...and 3 more locations